Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

(2013) Christopher Chapple et al.   EUROPEAN UROLOGY

Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison

(2013) Khaled Maman et al.   EUROPEAN UROLOGY

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

(2013) V. W. Nitti et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

A phase II dose-ranging study of mirabegron in patients with overactive bladder

(2013) Christopher R. Chapple et al.   INTERNATIONAL UROGYNECOLOGY JOURNAL

The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials

(2013) Yuanshan Cui et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

(2013) Sender Herschorn et al.   UROLOGY

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA

(2013) Karl-Erik Andersson   Therapeutics and Clinical Risk Management

Botulinum Toxin A Versus Placebo for Refractory Detrusor Overactivity in Women: A Randomised Blinded Placebo-Controlled Trial of 240 Women (the RELAX Study)

(2012) Douglas G. Tincello et al.   EUROPEAN UROLOGY

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

(2012) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

(2012) Vik Khullar et al.   EUROPEAN UROLOGY

Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline

(2012) E. Ann Gormley et al.   JOURNAL OF UROLOGY

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence

(2012) Anthony G. Visco et al.   NEW ENGLAND JOURNAL OF MEDICINE

Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

(2012) Georgia Salanti   Research Synthesis Methods

Efficacy and Safety of Low Doses of OnabotulinumtoxinA for the Treatment of Refractory Idiopathic Overactive Bladder: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Dose-Ranging Study

(2011) Pierre Denys et al.   EUROPEAN UROLOGY

Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China

(2011) Yuliang Wang et al.   NEUROUROLOGY AND URODYNAMICS

EAU Guidelines on Urinary Incontinence

(2010) Joachim W. Thüroff et al.   EUROPEAN UROLOGY

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

(2010) Roger Dmochowski et al.   JOURNAL OF UROLOGY

Current Information on Sacral Neuromodulation and Botulinum Toxin Treatment for Refractory Idiopathic Overactive Bladder Syndrome: A Review

(2010) Randall K. Leong et al.   UROLOGIA INTERNATIONALIS

Reviewing the ICS 2002 terminology report: The ongoing debate

(2009) Paul Abrams et al.   NEUROUROLOGY AND URODYNAMICS

Refractory Idiopathic Urge Urinary Incontinence and Botulinum A Injection

(2008) Linda Brubaker et al.   JOURNAL OF UROLOGY

Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units

(2008) Brian L. Cohen et al.   NEUROUROLOGY AND URODYNAMICS